Human umbilical blood mononuclear cell-derived mesenchymal stem cells serve as interleukin-21 gene delivery vehicles for epithelial ovarian cancer therapy in nude mice
- PMID: 22172102
- DOI: 10.1002/bab.63
Human umbilical blood mononuclear cell-derived mesenchymal stem cells serve as interleukin-21 gene delivery vehicles for epithelial ovarian cancer therapy in nude mice
Abstract
Ovarian cancer causes more deaths than any other cancer of the female reproductive system, and its overall cure rate remains low. The present study investigated human umbilical blood mononuclear cell (UBMC)-derived mesenchymal stem cells (UBMC-MSCs) as interleukin-21 (IL-21) gene delivery vehicles for ovarian cancer therapy in nude mice. MSCs were isolated from UBMCs and the expanded cells were phenotyped by flow cytometry. Cultured UBMCs were differentiated into osteocytes and adipocytes using appropriate media and then the UBMC-MSCs were transfected with recombinant pIRES2-IL-21-enhancement green fluorescent protein. UBMC-MSCs expressing IL-21 were named as UBMC-MSC-IL-21. Mice with A2780 ovarian cancer were treated with UBMC-MSC-IL-21 intravenously, and the therapeutic efficacy was evaluated by the tumor volume and mouse survival. To address the mechanism of UBMC-MSC-IL-21 against ovarian cancer, the expression of IL-21, natural killer glucoprotein 2 domain and major histocompatibility complex class I chain-related molecules A/B were detected in UBMC-MSC-IL-21 and in the tumor sites. Interferon-γ-secreting splenocyte numbers and natural killer cytotoxicity were significantly increased in the UBMC-MSC-IL-21-treated mice as compared with the UBMC-MSCs or the UBMC-MSC-mock plasmid-treated mice. Most notably, tumor growth was delayed and survival was prolonged in ovarian-cancer-bearing mice treated with UBMC-MSC-IL-21. Our data provide important evidence that UBMC-MSCs can serve as vehicles for IL-21 gene delivery and inhibit the established tumor.
Copyright © 2011 International Union of Biochemistry and Molecular Biology, Inc.
Similar articles
-
Gene therapy of ovarian cancer using IL-21-secreting human umbilical cord mesenchymal stem cells in nude mice.J Ovarian Res. 2014 Jan 20;7:8. doi: 10.1186/1757-2215-7-8. J Ovarian Res. 2014. PMID: 24444073 Free PMC article.
-
[Human umbilical cord mesenchymal stem cells with adenovirus-mediated interleukin 12 gene transduction inhibits the growth of ovarian carcinoma cells both in vitro and in vivo].Nan Fang Yi Ke Da Xue Xue Bao. 2011 May;31(5):903-7. Nan Fang Yi Ke Da Xue Xue Bao. 2011. PMID: 21602155 Chinese.
-
Augmenting therapy of ovarian cancer efficacy by secreting IL-21 human umbilical cord blood stem cells in nude mice.Cell Transplant. 2011;20(5):669-80. doi: 10.3727/096368910X536509. Epub 2010 Nov 5. Cell Transplant. 2011. PMID: 21054951
-
Murine bone marrow-derived mesenchymal stem cells as vehicles for interleukin-12 gene delivery into Ewing sarcoma tumors.Cancer. 2009 Jan 1;115(1):13-22. doi: 10.1002/cncr.24013. Cancer. 2009. PMID: 19051291 Free PMC article. Review.
-
Inflammatory Mediators in Glioma Microenvironment Play a Dual Role in Gliomagenesis and Mesenchymal Stem Cell Homing: Implication for Cellular Therapy.Mayo Clin Proc Innov Qual Outcomes. 2020 Aug 5;4(4):443-459. doi: 10.1016/j.mayocpiqo.2020.04.006. eCollection 2020 Aug. Mayo Clin Proc Innov Qual Outcomes. 2020. PMID: 32793872 Free PMC article. Review.
Cited by
-
Application of Mesenchymal Stem Cells for Therapeutic Agent Delivery in Anti-tumor Treatment.Front Pharmacol. 2018 Mar 20;9:259. doi: 10.3389/fphar.2018.00259. eCollection 2018. Front Pharmacol. 2018. PMID: 29615915 Free PMC article. Review.
-
Mesenchymal Stem/Stromal Cells as a Vehicle for Cytokine Delivery: An Emerging Approach for Tumor Immunotherapy.Front Med (Lausanne). 2021 Aug 27;8:721174. doi: 10.3389/fmed.2021.721174. eCollection 2021. Front Med (Lausanne). 2021. Retraction in: Front Med (Lausanne). 2023 Sep 04;10:1285195. doi: 10.3389/fmed.2023.1285195. PMID: 34513882 Free PMC article. Retracted. Review.
-
Mesenchymal stem/stromal cell-based therapy: mechanism, systemic safety and biodistribution for precision clinical applications.J Biomed Sci. 2021 Apr 14;28(1):28. doi: 10.1186/s12929-021-00725-7. J Biomed Sci. 2021. PMID: 33849537 Free PMC article. Review.
-
Mesenchymal Stem/Stromal Cell-Based Delivery: A Rapidly Evolving Strategy for Cancer Therapy.Front Cell Dev Biol. 2021 Jul 12;9:686453. doi: 10.3389/fcell.2021.686453. eCollection 2021. Front Cell Dev Biol. 2021. Retraction in: Front Cell Dev Biol. 2023 Sep 04;11:1285267. doi: 10.3389/fcell.2023.1285267. PMID: 34322483 Free PMC article. Retracted. Review.
-
Interleukin gene delivery for cancer gene therapy: In vitro and in vivo studies.Iran J Basic Med Sci. 2023 Feb;26(2):128-136. doi: 10.22038/IJBMS.2022.66890.14668. Iran J Basic Med Sci. 2023. PMID: 36742134 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical